Clinical Trial

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing The Efficacy And Safety Of LOU064 100 Mg BID Versus Teriflunomide 14 Mg QD In Participants With RMS, Followed By Extended Treatment With Open-Label LOU064

Study Status:

Open for enrollment

Contact Information:

(956) 362-2391

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To demonstrate that LOU064 (100 mg PO bid) is superior to teriflunomide (14 mg PO once daily) in reducing the frequency of confirmed relapses as evaluated by the annualized relapse rate (ARR) in Participants with relapsing MS.

Information:

Principal Investigator	Roberto A. Cruz Saldana, M.D.
Co-PI	Esmeralda Cordoso-Mendoza
Sponsor	Novartis
Type of Trial	Interventional

Contact Us For More Info Or To Apply

5323 S. McColl Rd., Edinburg, TX 78539

[email protected]

(956) 362-2390

Clinical Trial

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing The Efficacy And Safety Of LOU064 100 Mg BID Versus Teriflunomide 14 Mg QD In Participants With RMS, Followed By Extended Treatment With Open-Label LOU064

Study Status:

Contact Information:

Study Purpose:

Information:

Useful Links

For Research Participants

About Us

News & Views